Abstract
On the basis of the well recognised role of inflammation in the pathogenesis of asthma, anti-inflammatory therapy, in the form of inhaled corticosteroids, has become the mainstay of treatment in patients with persistent asthma. Budesonide inhalation suspension (BIS) is a nonhalogenated corticosteroid with a high ratio of local anti-inflammatory activity to systemic activity. Furthermore, BIS is approved in >70 countries for the maintenance treatment of bronchial asthma in both paediatric and adult patients (approval is limited to paediatric patients in the US and France).
Randomised, double-blind, placebo-controlled trials conducted in >1000 children have demonstrated the efficacy of BIS in children with persistent asthma of varying degrees of severity. In children frequently hospitalised with uncontrolled asthma, initiation of BIS therapy can reduce the need for emergency intervention. Moreover, limited data suggest that BIS is effective for the treatment of acute exacerbations of asthma in children and may reduce the need for short courses of oral corticosteroids.
BIS is well tolerated in children, with an adverse event profile similar to that of placebo, and no clinically relevant changes in adrenal function have been demonstrated during the course of short- and long-term (1-year) studies. Small but statistically significant reductions in growth velocity have been demonstrated with BIS over 1 year of treatment. However, available evidence suggests that growth effects are transient in children receiving budesonide and that these children eventually achieve full adult height.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication No. 02-3659. Issued January, 1995 (updated 2002). Management segment (chapter 7): updated 2003 from the 2002 document: 1-180 [online]. Available from URL: http://www.ginasthma.com [Accessed 2005 Aug 9]
AAAAI. Pediatric asthma: promoting best practice. Guide for managing asthma in children. Milwaukee (WI): American Academy of Allergy, Asthma & Immunology, 2004: 1–143
American Lung Association, Epidemiology & Statistics Unit, Research and Scientific Affairs. Trends in asthma morbidity and mortality. 2004 Apr [online]. Available from URL: http://www.texaslung.org/educationalresources/diseases/asthma/2004asthmatrends.pdf [Accessed 2005 Jul 22]
National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics 2002. J Allergy Clin Immunol 2002; 110 (5 Suppl.): S141–219
Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 176–83
Tasche MJA, Uijen JHJM, Bernsen RMD, et al. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systemic review. Thorax 2000; 55: 913–20
Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998 Oct; 102(4): 531–8
Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992 Sep; 44(3): 375–407
Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000 Nov; 60(5): 1141–78
Szefler SJ. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immunol 1999 Oct; 104(4): S175–83
Agertoft L, Andersen A, Weibull E, et al. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child 1999 Mar; 80(3): 241–7
Pulmicort Respules [summary of product characteristics]. Luton: AstraZeneca UK Ltd, 2001 Jun 11
Pulmicort Respules (budesonide inhalation suspension) prescribing information. Wilmington (DE): AstraZeneca LP, 2004 Mar
de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol 1996 Jul; 98(1): 14–20
Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child 1993 Mar; 68(3): 356–9
Wennergren G, Nordvall SL, Hedlin G, et al. Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr 1996; 85: 183–9
Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999 Feb; 103(2): 414–21
Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999 Sep; 83: 231–9
Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998 Nov; 102(5): 789–96
Mellon M, on behalf of the Budesonide Inhalation Suspension Study Group. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999 Oct; 104: S191–9
Leflein JG, Gawchik SM, Galant SP, et al. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy Asthma Proc 2001 Nov–Dec; 22(6): 359–66
Scott MB, Ellis MH, Cruz-Rivera M, et al. Once-daily budesonide inhalation suspension in infants and children <4 and ≥4 years of age with persistent asthma. Ann Allergy Asthma Immunol 2001 Dec; 87(6): 488–95
Mendelson L, Cook D, Cruz-Rivera M, et al. Twice-daily budesonide inhalation suspension in infants and children <4 and ≥4 years of age with persistent asthma. J Asthma 2002 May; 39(3): 227–37
Leflein JG, Szefler SJ, Murphy KR, et al. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. Pediatrics 2002 May; 109(5): 866–72
Chipps BE, Schnepp CM, Briscoe M. Budesonide inhalation suspension reduces the need for emergency intervention in pediatric asthma: a named-patient case series. J Asthma 2003 Dec; 40(8): 895–900
Murphy KR, Fitzpatrick S, Cruz-Rivera M, et al. Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma. Pediatrics 2003 Sep; 112(3): e212–9
Delacourt C, Dutau G, Lefrançois G, et al. Comparison of the efficacy and safety of nebulized beclometasone dipropionate and budesonide in severe persistent childhood asthma. Respir Med 2003 Feb; 97 Suppl. B: S27–33
Terzano C, Allegra L, Barkai L, et al. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma. Eur Rev Med Pharmacol Sci 2000; 4: 17–24
van Staa TP, Cooper C, Leufkens HG, et al. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003 May; 18(5): 913–8
Kaye LD, Kalenak JW, Price RL, et al. Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 1993 May–Jun; 30(3): 142–4
Abernathy-Carver KJ, Fan LL, Boguniewicz M, et al. Legionella and Pneumocystis pneumonias in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol 1994 Sep; 18(3): 135–8
Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 2001 Feb; 3(1): 17–21
Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med 1998 Mar; 5(3): 209–13
Matthews EE, Curtis PD, McLain BI, et al. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr 1999 Aug; 88(8): 841–3
Daugbjerg P, Brenoe E, Forchhammer H, et al. A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. Acta Paediatr 1993 Jun–Jul; 82(6–7): 547–51
Devidayal D, Singhi S, Kumar L, et al. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr 1999 Aug; 88(8): 835–40
Volovitz B, Bentur L, Finkelstein Y, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol 1998 Oct; 102: 605–9
Sano F, Cortez GK, Solé D, et al. Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone. J Allergy Clin Immunol 2000 Apr; 105(4): 699–703
Volovitz B, Soferman R, Blau H, et al. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunl 1998 Apr; 101 (4 Pt 1): 464–9
Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999 Oct; 104 (4 Pt 2): S200-9
Szefler SJ, Lyzell E, Fitzpatrick S, et al. Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. Ann Allergy Asthma Immunol 2004 Jul; 93(1): 83–90
Berger WE, Qaqundah PY, Blake K, et al. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr 2005 Jan; 146(1): 91–5
Irani A-M, Cruz-Rivera M, Fitzpatrick S, et al. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol 2002 Mar; 88(3): 306–12
Skoner DP, Szefler SJ, Welch M, et al. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol 2000 Feb; 105(2): 259–68
Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther 2004 Nov; 26(11): 1905–19
Doull IJM. The effect of asthma and its treatment on growth. Arch Dis Child 2004 Jan; 89(1): 60–3
Creese KH, Doull IJ. Effects of inhaled corticosteroids on growth in asthmatic children. Curr Allergy Asthma Rep 2001 Mar; 1(2): 122–6
Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000 Oct; 343(15): 1054–63
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000 Oct; 343(15): 1064–9
de Jongste JC, Duiverman EJ. Nebulized budesonide in severe childhood asthma [letter]. Lancet 1989; 333(8651): 1388
Grimfeld A, Lesbros D, Ostinelli J, et al. Long-term study of nebulised budesonide in young children with moderate to severe asthma [abstract no. 0204]. Eur Respir J 1994; 7 Suppl. 18: 27S
Lødrup Carlsen CKC, Carlsen KH, Nikander K, et al. Nebulized budesonide after hospitalisation for recurrent bronchial obstruction in children younger than 18 months. Pediatr Allergy Immunol 2000; 12: 159–65
Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 1999; 12(2): 47–53
Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998; 11(2): 113–25
Vikre-Jørgensen J, Agertoft L, Pedersen S. Dose titration of nebulized budesonide in young children. Pediatr Pulmonol 1997; 23: 270–7
Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child 1992; 67: 586–91
Geller DE, Kesser KC, Janssens HM, et al. Delivery of budesonide inhalation suspension (BIS) through an infant upper airway model [poster]. 99th International Conference of the American Thoracic Society; 2003 May 16–23; Seattle (WA)
Mellon M, Leflein J, Walton-Bowen K, et al. Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 2000 Aug; 162(2): 593–8
Georgitis JW, McWilliams B, Cruz-Rivera M, et al. Effective once-daily administration of budesonide inhalation suspension by nebulizer with facemasks or mouthpieces for persistent asthma in infants and young children. Pediatr Asthma Allergy Immunol 2001; 15(1): 3–13
McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004 Jun; 38(6): 967–72
Dunlop KA, Carson DJ, Shields MD. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Pediatr Pulmonol 2002 Jul; 34(1): 85–6
Zwaan CM, Odink RJH, Delemarre-van de Waal HA, et al. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy [letter]. Lancet 1992 Nov; 340(8830): 1289–90
Acknowledgements
The author acknowledges Leslie Sell from Thomson Scientific Connexions for assistance in writing the manuscript. Editorial support was provided by AstraZeneca LP.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berger, W.E. Budesonide Inhalation Suspension for the Treatment of Asthma in Infants and Children. Drugs 65, 1973–1989 (2005). https://doi.org/10.2165/00003495-200565140-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200565140-00005